USE OF D-TAGATOSE AS A PREBIOTIC FOOD COMPONENT

Abstract: Oral intake of D-tagatose in a prebiotic food induces production of butyrate and stimulates the growth of beneficial bacteria in the human colon. Therefore it is believed to be useful in food or the like as preventive drug against colon cancer.

Description: Use of D-tagatosθ as a prebiotic food component Background of the invention 1. Field of the invention This invention relates to the use of D-tagatose as a pre ¬ biotic component. It can be used as a prebiotic food, food additive or food supplement. Tests have surprisingly shown that oral intake of the un- absorbable carbohydrate, D-tagatose, induces production of butyrate in colon. From the literature it is known that butyrate possibly has a colon cancer protective ef- feet. Further, tests have shown that oral intake of D-tagatose stimulates the growth of beneficial lactoba- cilli and lactic acid bacteria in the human colon. There ¬ fore, D-tagatose is useful as a prebiotic food to stimu ¬ late the growth of beneficial bacteria and to induce the production of butyrate. Such prebiotic food is thus presumably useful for normalizing the bacterial flora in the colon and for preventing the risk of colon cancer in human beings. D-tagatose is a well-known keto-hexose which is useful as a reduced-calorie food sweetening and bulking agent, and as an additive in detergent, cosmetic and pharmaceutical formulations. U.S. Patents Nos. 5,002,612 and 5,078,796 to Beeadle et al. teach processes of making D-tagatose by isomerizing a mixture containing D-galactose with a metal hydroxide in the presence of a catalyst at a relatively low temperature to form an intermediate complex, followed by neutralization with acid to yield D-tagatose. D-tagatose is known as an anti-hyperglycaemic agent that can be used to inhibit formation of advanced glycosyla- tion in products in mammals, as described in U.S. Patents 5,356,879 and 5,447,917 to Zehner et al . D-tagatose also is known as a low-calorie carbohydrate sweetener and bulking agent that can be used in the preparation of sweetened edible formulations in stead of sucrose, as taught in U.S. Patent 4,786,722 to Zehner. 2. Description of the Related Art The mucosal surfaces of the intestinal tract are amongst the main sites of cell replication in the human body. In the colon the epithelial cells are exposed not only to the circulation and to the endogenous secretions of other mucosal cells, but also to the contents of the colonic lumen which is rich in food residues and the metabolic products of the micro flora. (I. T. Johnson "Butyrate and markers of neoplastic change in the colon", European Journal of Cancer Prevention, Vol. 4, 1995) . Epidemiol- ogical and animal studies suggest that dietary fat and protein may promote carcinogenesis in the colon, whereas increases in fibre and complex carbohydrates in the diet may protect against colon cancer. Colonic luminal bu ¬ tyrate concentrations are postulated to be the key pro ¬ tective component of high-fibre diets against colon can- cer (O.C. Velazquez, H.W. Lederer and J.L. Rombeau 1996. "Butyrate and the Colonocyte: Implications for Neopla- sia", Digestive Diseases and Science Vol. 41, No. 4: 727- 739) . Butyrate is one of the short-chain fatty acids (SCFA) , i.e. the C2-5 organic acids. These compounds are formed in the gastrointestinal tract of mammals as a result of anaerobic bacterial fermentation of undigested dietary components, and are readily absorbed by the colonic epi- thelium. Dietary fibre is the principal substrate for the fermentation of SCFA in humans, however, intake of fibres is often low in a typical western diet. Other undigested components, like starch, proteins, contribute to the production of SCFA, but also low-molecular weight oligosac- charides, sugars, and polyols, which escape digestion and absorption in the small intestine, contribute to the production of SCFA. In the mammalian hind gut, acetate, propionate, and butyrate account for at least 83 c of SCFA and are present in a nearly constant molar ratio 60:25:15 (Velazquez et al . , supra). In vi tro studies on fibre and other indigestible carbohydrates in human faecal incubations indicate 3-22 butyrate, only various forms of starches and resistant starches had a butyrate proportion of 22-29° (F. Bornet, C. Alamowitch and G. Slama 1994. "Acides Gras Volatils: Des actions sur le metabolisme glucidique", Rev Prat 44 (8) : 1051-1055) . Similarly, ileal effluents from pigs eating beet fibre and barley bran incubated in human fae ¬ cal slurry in vi tro incubation did not increase the pro- portion of butyrate beyond the 18"- observed with ileal effluents from a fibre free pig diet (A. Fardet, F. Guil- lon, C. Hoebler and J-L. Barry 1997. " In vi tro fermentation of beet fibre and barley bran, of their insoluble residues after digestion and ileal effluents", J. Sci Food Agric 75: 315-325) .In a pig study ingesting either raw potato starch, hylon starch or retrograded hylon starch, the molar proportion of butyrate was not higher than 14% at the highest level, which was in the proximal colon, and similarly the in vi tro incubation showed only between 14 and 25% butyrate (mol%) (L.J.M. Martin, H.J.W. Dumon and M.M. J. Champ 1998. "Production of short-chain fatty acids from resistant starch in a pig model", J. Sci. Food Agric. 77:71-80. A study of fermentation of mono- and disaccharide in a human faecal in vi tro system, indicated a high proportion of butyrate on fermentation of sorbitol, galacturonic acid and glucoronic acid (P. B. Mortensen, K. Holtug and H.S. Rasmussen 1988, "Short-chain fatty acid production from mono- and disaccharides in a faecal incubation sys- tem: Implications for colonic fermentation of dietary fi ¬ ber in humans", J. Nutr. 118:321-325). The findings of high butyrate with sorbitol are not confirmed on incuba ¬ tion with maltitol, which consists of 50% glucose and 50° sorbitol, as in vi tro incubation of maltitol only indi- cated 10% butyrate (A. Rapaille and F. Bornet, "Maltitol, recent findings on colonic health", FIE London 1997) . The colonic epithelium is a dynamic tissue in a state of continual renewal. Cells proliferate in the lower two- thirds of the normal colonic crypt, and cease dividing as they migrate further up the crypt. The continuous movement of cells up the colonic crypt is tightly linked to differentiation (A. Hague, A. J. Butt and C. Paraskeva 1996 "The role of butyrate in human colonic epithelial cells: An energy source or inducer of differentiation and apoptosis", Proceedings of the Nutrition Society 55:937- Butyrate appears to be of central importance to the colonic epithelium because it is the major and preferred fuel (W.E.W. Roediger 1980, "Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man", Gut 21:793-798) and plays a role in the control of prolifera- tion and differentiation of colonic epithelial cells. Many studies have demonstrated that butyrate is trophic to the colonic mucosa at physiological concentrations, and this is due to an acceleration of crypt cell proliferation (Johnson, supra) . In many tissues undergoing rapid turnover of cells, apop- tosis is involved in the maintenance of tissue homeosta ¬ sis. In the gut, where the epithelial cells are exposed to dietary carcinogens, cells undergo apoptosis as a means of eliminating damaged cells and, thus, protecting the tissue against neoplastic changes. Several in vi tro studies have indicated that butyrate causes apoptosis at physiological concentrations (2-4 mM) (A. Hague and C. Paraskeva "The short-chain fatty acid butyrate induces apoptosis in colorectal tumor cell lines", European Jour ¬ nal of Cancer Prevention, Vol. 4, 1995) . In contrast to the above mentioned trophic effect of bu ¬ tyrate on normal mucosa, the growth of neoplastic colono- cytes is arrested by butyrate, which also inhibits the preneoplastic hyper proliferation induced by tumor promo- tor in vi tro . The uncontrolled growth of cancer cell lines is stopped, and differentiation is induced by bu ¬ tyrate (Velazquez et a]., supra). The lactobacilli are important inhabitants of the intestinal tract of man and animals. Lactobacillus species, notably Lactobacillus acidophilus, are most often impli ¬ cated in assisting the establishment of a 'normal micro flora', especially following antibiotic therapy. In addition, probiotic lactobacilli have been implicated in a variety of beneficial roles, including (T. R. Klaenhammer 1998, "Functional activities of lactobacillus probiotics: Genetic mandate", Int. Dairy Journal 8:497-505): Mainte- nance of the normal micro flora, pathogen interference, exclusion and antagonism, immunostimulation and immuno- modulation, anticarcinogenic and a timutagenic activities, deconjugation of bile acids, lactase presentation in vivo . Another effect mentioned of lactobacillus is reduction in blood cholesterol (C. Daly, G.F. Fitzgerald, L. O'Conner and R. Davis 1998, "Technological and health benefits of dairy starter cultures", Int. Dairy Journal 8:195-205). A lot of studies on probiotic bacteria have shown that it is very difficult for these bacteria to colonize the hu ¬ man colon, that is after having stopped supply of pro ¬ biotic bacteria in the diet, they disappear from faeces. This makes it more obvious to isolate possible probiotic bacteria from the human intestine (U.S. Patent 5,709,857) . It is even more obvious to selectively feed the lactobacillus already present in the colon (prebiotic concept) . The literature on beneficial effects and mechanism on both butyrate and lactobacillus is very abundant, so only recent review type articles are referred to in this sec ¬ tion. Summary of the Invention D-tagatose is a naturally-occurring keto-hexose which only differs from D-fructose at the fourth carbon atom. The rather small difference has big implications on the overall metabolism of D-tagatose, as only 15-20% of ingested D-tagatose is absorbed in the small intestine. The major part of ingested D-tagatose is fermented in the co ¬ lon by indigenous micro flora resulting in production of short-chain fatty acids (SCFA) . The novelty of D-tagatose is that the fermentation induces a very unique profile of SCFA's with a high proportion of butyrate. These findings are documented in in vi tro and in vi vo studies in pig and in human faecal in vi tro experiments. Human studies document that generally accepted beneficial bacteria, like lactobacilli and lactic acid bacteria, are increased in human faeces upon ingestion of D-tagatose. Being a potential future food ingredient with a sweetness similar to sucrose, D-tagatose is an ideal ingredient for application in a range of food products. The ideal fer ¬ mentation products of D-tagatose with a high proportion of butyrate and stimulation of growth of lactobacilli make D-tagatose an ideal future prebiotic food ingredient that keeps a healthy balance in the colon and may have even a cancer protective role. Thus, the invention relates to use of D-tagatose as a prebiotic food , food additive or food supplement. D-tagatose has been shown to induce production of butyrate by bacteria in the human colon and to stimulate growth of lactobacilli and lactic acid bacteria in the human colon. This makes D-tagatose a possible candidate for the production of a drug for preventing colon cancer. D-tagatose can be taken orally in an effective amount to induce production of butyrate in the human colon and/or to stimulate the growth of lactobacilli and lactic bacte ¬ ria in the human colon. Such amount will normally be 5 to 30 gram, and preferably 5 to 15 gram a day taken 1-3 times a day. D-tagatose can be taken in any normal food product, such as confectionery, chewing gum, ice cream, dessert, soft drink, breakfast cereal, yoghurt, health drink or health bar. It has been proposed to substitute sucrose or to sweeten such products using D-tagatose. It is of course also possible to use D-tagatose as such, for example as a sweetener in coffee, tea or the like, or to take it as it is or in a formulated form, such as tablets. The amounts effective to achieve the useful effects according to the invention are the same as normally used to sweeten food products and/or to give them the normal bulk effect. This is achieved by incorporation of 10 - 20% by weights of D-tagatose in breakfast cereals, where the normal serving is 60 g, 5 - 10% by weight of D-tagatose in breakfast yoghurt, where the normal serving is 150 g. Further, it is proposed to incorporate 2 - 4% by weight in health drinks, where the normal serving is 250 - 330 ml and 20 - 30 % by weight in health bars, where the nor ¬ mal serving is 30 to 50 g. The accompanying drawing illustrates the invention. Fig. 1 shows the concentration of butyrate in various gastrointestinal sections. Fig. 2 shows the 12 hour in vi tro production of bu ¬ tyrate in the content from different gut sec- tions. Fig. 3 shows the total 12 hour in vitro production of SCFA. Fig. 4 shows the butyric acid absorption in the blood. Fig. 5 shows the influence of D-tagatose on bacterial composition in human faeces. Detailed description of the Invention The invention is further illustrated by the following non-limiting examples. Example 1 : In the study, one group of 8 pigs was having a standard diet + 15% sucrose (unadapted) , and another group of 8 pigs was fed a standard diet +5% sucrose + 10% D-tagatose (adapted) for 17 days. On the 17th day the pigs were killed 3 hours after the morning feeding, and the entire gastrointestinal tract was sectioned. Content from mid-colon was used for in vi ¬ tro fermentation assays. 20% slurries were incubated at 37° C and anaerobic conditions for 4 hours with or with ¬ out 1% D-tagatose added. The amount of SCFA produced by D-tagatose is calculated as the amount produced in the assay with 1% D-tagatose added subtracted by the amount produced in the assay without D-tagatose. Table 1 shows that colon content from adapted pigs fer- ments D-tagatose in a very special way with low acetate and high butyrate and valerate, whereas the colon content from unadapted pigs gives a rather normal SCFA profile with less than 20% butyrate and a high proportion of acetate. The overall fermentation rate, measured as rate of degradation of D-tagatose, is low in in vi tro incubation with D-tagatose in unadapted pigs, 1.1 g of D-tagatose pr hour pr kg digesta versus 15.3 g of D-tagatose pr hour pr kg digesta in adapted pigs. 10 Tabl e 1 In vitro Incubations - 3 Hours after Slaughtering Mole % of SCFA after microbial fermentation of D-Tagatose Control pigs D-tagatose pigs caecum colon caecum colon Formate 2.5 0.0 14.4 3.7 Acetate 54.8 70.1 21.5 23.3 Propionate 11.2 0.0 17.0 4.0 Butyrate 18.2 16.7 21.8 46.3 Valerate 11.1 7.8 23.4 15.1 Capronate 2.0 4.8 1.9 6.8 Heptanoate 0.2 0.6 0.0 0.8 Total 100.0 100.0 100.0 100.0 Tagatose 2.7 1.1 3.7 15.3 degradation g/h/kg di gesta Production (0-4 h) of SCFA SCFA (1% tagatose added) - SCFA (no tagatose added) Example 2: In this study, 3 groups of each 2 pigs were having a standard pig diet + 20% sucrose, a standard pig diet + 10% sucrose + 10% D-tagatose, and a standard pig diet + 20% D-tagatose for 33 days. The pigs were killed on the 33. day 6 hours after morning feeding, and the entire gastrointestinal tract was divided into 8 segments. The concentrations of the various SCFA were measured in the 8 sections immediately after killing, and further the 11 content from the 8 sections was used for 12 hour in vi tro incubations at 37 °C and anaerobic conditions. In this in vi tro assay no D-tagatose was added, and the fermentation products originate from unabsorbed D-tagatose and other undigestible food components from the diets. Fig. 1 shows the concentration of butyrate in the various gastrointestinal sections at the time of slaughtering. The results clearly indicate that butyrate is present only in the hind gut, as expected, and that butyrate is increasing in a dose response manner to the intake of D-tagatose . Fig. 2 shows that the 12 hour in vi tro production of bu- tyrate similarly is acting in a dose response manner to the intake of D-tagatose in the diet. The following abbrevations are used in figures 1 and 2: st = stomach Sll = small intestine section 1 512 = small intestine section 2 513 = small intestine section 3 Cae = caecum Col = colon section 1 Co2 = colon section 2 Rec 0 rectum Fig. 3 shows the total 12 hour in vi tro production of SCFA in the gut, that is the in vi tro production rate of SCFA multiplied by the amount of gut material in the various sections. The data presented here are normalized to production of SCFA pr kg feed. The data clearly indicate that the addition of D-tagatose to the diet, in a dose response manner promote the micro- 12 biological production of butyrate, whereas the total pro ¬ duction of acetate is not influenced. The following abbrevations are used in figure 3: For = formic acid (formate) Acet = acetic acid (acetate) Prop = propionic acid (propionate) I-but = iso-butyric acid (iso-butyratet ) But = butyric acid (butyrate) I-val = iso-valeric acid (iso-valerate) Val - valeric acid (valerate) Cap = capronic (capronate) Lact = lactic acid (lactate) Example 3 : In this pig study the in vi vo absorption of SCFA in the blood is measured by taking blood samples simultaneously from 3 catheters in Vena Mesenterica, Ateria mesenterica and Vena Porta over a 12 hour period after the morning feeding. The absorption is measured in the same 5 pigs at 3 different occasions, that is after 7 days adaptation to standard pig diet + 20% sucrose (sucrose) , the first day of switching to a standard pig diet + 20% D-tagatose (unadapted) , and after 7 days adaptation to a standard pig diet + 20% D-tagatose (adapted) . The concentration of SCFA's is determined in samples from the portal vein, that is the blood stream leading from the digestive system to the liver, and in the arterial blood, that is the blood stream before the digestive system. The difference between the two integrated by time is a measure of the intestinal absorption of SCFA's. Fig. 4 shows the concentration of butyrate in the portal vein and in the arterial blood as a function of time af- 13 ter feeding. The area between the 2 curves is equal to the total absorption of butyrate from the intestine. When the pigs were on the 20% sucrose diet, the concen- tration of butyrate in the portal vein is low and stable over time and very low in the arterial blood, indicating that the absorbed butyrate is cleared by the liver. In the 2. period, unadapted to the 20% D-tagatose diet, the amount of butyrate in the portal vein is gradually in- creasing over the 12 hours of measuring. When the pigs were measured after 7 days of adaptation to the 20" D- tagatose diet, the concentration of butyrate in the por ¬ tal blood shows a very steep increase a few hours after feeding, and also the concentration in arterial blood is increasing, indicating that the liver is no longer able to clear the portal vein absorbed butyrate. The total absorption of butyrate represented by the area between the 2 curves does not differ in the adapted and unadapted state . The absorption of acetate and propionate is not increased by addition of D-tagatose to the diet. The in vi vo absorption of butyrate in the portal vein does not directly reflect the production of butyrate in the colon. Under normal conditions a great part of the produced butyrate is utilized by the colonic mucosa before entering the blood. The very large in vi vo absorption of butyrate merely reflects a production of butyrate in the colon that far exceeds the utilisation by the mucosal cells. These absorption data clearly support a D-tagatose induced production of butyrate in vi vo r and that the adap- tation to butyrate production takes place within 12 hours . 1 4 Exampl e 4 : In this study 16 human volunteers deliver a faeces sample before any intake of D-tagatose (unadapted) and another faeces sample after 14 days' intake of 3 x 10 g of D-tagatose pr day (adapted) . The 16 volunteers are on controlled diet 4 days before the delivery of each faeces samples. Faeces slurries , 20%, were incubated at 37° C and anaerobic conditions for 48 hours with or without 1% D-tagatose added. Samples for determination of SCFA were taken after 4 hours and after 48 hours of incubation. The amount of SCFA produced by D-tagatose is calculated as the amount produced in the assay with 1% D-tagatose added subtracted by the amount produced in the assay without D-tagatose. Further, the delivered faeces samples were tested for content of various intestinal bacteria counts by spreading on selective media. Table 2 shows the mol% of the various SCFA produced in vi tro by D-tagatose in the unadapted and adapted state, and also the actually produced total SCFA in mmol pr 1 of incubation slurry. 15 Tabl e 2 In Vitro Fermentation of Tagatose by Incubation of Human Faeces Molar Ratios (Mole%) of SCFA ' s 4 hours of incubation 48 hours of incubation Non-adapted Adapted Non-adapted Adapted Formic acid 0.5 5.8 0.0 0.1 Acetic acid 62.8 42.1 37.7 35.3 Propionic 0.0 4.1 0.0 0.5 acid Butyric acid 24.5 34.7 38.7 47.0 Valeric acid 3.0 1.0 1.2 1.6 Capronic 6.7 3.5 15.2 13.5 acid Heptanic 1.1 0.6 1.6 1.2 acid Lactic acid 3.9 9.0 8.6 3.0 Total 100.0 100.0 100.0 100.0 Total SCFA 8.8 24.3 49.0 44.0 (production mmol/1) The production of SCFA is 8.8 mmol/1 and 24.3 mmol/1 after 4 hours of incubation in the unadapted and adapted state, respectively. The ratio of butyrate after 4 hours of incubation is also higher in the adapted state and much higher than the normally observed 15-20%. After 48 hours of incubation there is no longer any difference in the amount of SCFA produced, and the proportion of butyrate is high both in the adapted and unadapted incuba- 1 6 tions. These data also support a D-tagatose induced pro ¬ duction of butyrate, and an adaptation in the in vi tro incubation system within 48 hours. Fig. 5 shows the results of counting bacteria (log scale) on different selective media. The number of lactobacilli and lactic acid bacteria is increased in number, and en- tero-bacteria is decreased in faeces of human volunteers ingesting D-tagatose for 14 days compared to the same persons not ingesting D-tagatose. The following abbrevations are used in figure 5: coli = coliform bacteria LNE = lactose neg. enterobacteria LAB = lactic acid bacteria LAC = lactobacilli Ent = enterococci Tot an = anaerobes Bac = bacteroides Bif = bifidobacteria Conclusion The 2 in vi tro studies in pigs (Examples 1 and 2) with addition of D-tagatose and relying on D-tagatose escaping absorption in the small intestine, showed a D-tagatose induced butyrate production. More importantly, the con ¬ centration in the colon of pigs immediately after slaugh- ter, reflecting the concentrations in vi vo, showed a dose response increase in butyrate concentration to the amount of D-tagatose ingested. Even more importantly, the in vivo absorption of butyrate in the portal vein documents a very prominent butyrate inducing effect of D-tagatose. 17 None of these above mentioned studies in pigs, that is taking of samples of colon content and blood samples from the portal vein, can be performed in humans for ethical reasons. However, pig and human have the same structure of the gastrointestinal tract and harbors qualitatively the same types of intestinal bacteria, so the pig serves as a good model for humans in digestion and fermentation. To perform human studies, one has to rely on in vi tro studies with D-tagatose added to human faecal slurries. These studies showed the same trends of D-tagatose in ¬ duced butyrate production as in the pig incubations per ¬ formed with colon content slurries. The intestine of both pig and human harbors bacteria which have butyrate as the fermentation end product. D-tagatose is a rather rare sugar for intestinal bacteria and is only fermented by a limited number of genera of bacteria, enterococci, lactobacilli, and obviously some butyrate producing intestinal bacteria. Other fibres or undigested carbohydrates are either not a substrate for butyrate producing bacteria, or competition for the de ¬ livered substrate favours growth of other bacteria. A reasonable explanation for the butyrate inducing effect of D-tagatose is that butyrate producing bacteria is fa- voured over most other bacteria when supplying D-tagatose. The adaptation seen with ingestion of D-tagatose in both pigs and human volunteers is probably due to selection of butyrate producing bacteria in the colon. The in vi vo absorption study in pigs showed that the adaptation or selection of bacteria takes place already within 12 hours. Similarly, the in vi tro study with human faeces indicates selection of bacteria within the 48 hours of incubation. Overall, between 10 and 60 g of carbohydrate containing compounds become available to the human flora on a daily basis and constitute the major influence on intraluminal events (G.T. Mcfarlane and J.H. Cummings 1991. The colonic flora, fermentation, and large bowel digestive function; In The large intestine: Physiology, pathophysiol- ogy, and disease, Ed: S.F. Phillips, J. H. Pemberton and R.G. Shorter. Raven Press, Ltd., New York). The intake of D-tagatose is, like all other unabsorbable carbohydrates, in practice limited in intake by gastrointestinal side effects. Oral intake 5-30 g of D-tagatose pr day aiming at a pre-biotic effect is very easily achieved as D- tagatose can be incorporated in almost any food, but most obviously in applications as a substitute for sucrose, for example , as mentioned, in confectionery and chewing gum, ice cream and other desserts, yoghurts, cereals and energy bars, soft drinks and health drinks.

Claims: 19 Claims 1. Use of D-tagatose as a prebiotic food, food additive or food supplement. 2. Use of D-tagatose according to claim 1 for inducing production of butyrate by bacteria in the human colon. 3. Use of D-tagatose according to claim 1 for stimulating growth of lactobacilli and lactic acid bacteria in the human colon. 4. Use of D-tagatose for the production of a drug for preventing colon cancer. 5. Use of D-tagatose according to any of the preceding claims, c h a r a c t e r i z e d in that D-tagatose is taken orally in an effective amount to induce production of butyrate in the human colon and/or to stimulate the growth of lactobacilli and lactic bacteria in the human colon. 6. Use of D-tagatose according to claim 4, c h a r a c t e r i z e d in that D-tagatose is taken orally in a daily amount of 5 to 30 gram. 7. Use of D-tagatose according to claim 5, c h a r a c t e r i z e d in that D-tagatose is taken orally in a daily amount of 5 to 15 gram. 8. Use of D-tagatose according to any of the preceding claims, c h a r a c t e r i z e d in that D-tagatose is taken orally in a food product or the like. 9. Use of D-tagatose according to claim 8, c h a r a c - 20 t e r i z e d in that the food product is chosen from the group consisting of confectionery, chewing gum, ice cream, dessert, soft drink, breakfast cereals, yoghurt, health drink or health bar.

Inventors: ANDERSEN HENRIK, VIGH MADS LIENDGAARD, ANDERSEN, HENRIK, VIGH, MADS, LIENDGAARD
Applicants: ANDERSEN HENRIK, MD FOODS AMBA, VIGH MADS LIENDGAARD, ANDERSEN, HENRIK, MD FOODS A.M.B.A., VIGH, MADS, LIENDGAARD
Application year: 1999
Main classification: A23L1
IPC codes: A23L1, A61K31, A61P3, A61P35, A61P43